Revenue
2024
2025
Zhengye Biotechnology Holding Ltd (ZYBT)
Price$1.61Cached quote
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $16.6M | $25.5M | — | — | — |
| Gross profit | $3.4M | $12.5M | — | — | — |
| Gross margin | 20.51% | 48.99% | — | — | — |
| Research & development | $2.6M | $1.8M | — | — | — |
| Operating expenses | $13.5M | $10.3M | — | — | — |
| Operating income | −$10.1M | $2.3M | — | — | — |
| Operating margin | −60.60% | 8.82% | — | — | — |
| EBITDA | −$6.4M | $5.6M | — | — | — |
| EBITDA margin | −38.36% | 21.79% | — | — | — |
| Net income | −$10.0M | $1.6M | — | — | — |
| Net profit margin | −59.99% | 6.07% | — | — | — |
| Basic EPSper basic share | — | $0.03 | — | — | — |
| Diluted EPSper diluted share | — | $0.03 | — | — | — |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Han Zhenfa | 42.96M |
XTX Topco Ltd | 48.87K |
GEODE CAPITAL MANAGEMENT, LLC | 29.07K |
WINTON GROUP Ltd | 12.73K |
UBS Group AG | 7.99K |
ROYAL BANK OF CANADA | 1.23K |
MORGAN STANLEY | 248 |
JPMORGAN CHASE & CO | 134 |
Caitong International Asset Management Co., Ltd | 1 |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 3 ↗Updated Sep 29, 2026 · Quarterly data